Eine Verlängerungsstudie, um Teilnehmenden mit soliden Tumoren, die zuvor an einer von Roche/Genentech gesponserten Studie teilgenommen haben, weiterhin eine Bevacizumab-Therapie bereitzustellen

An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/​Genentech Sponsored Study

  • Krebs
  • Tumor
  • Neoplasien
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:

Abgeschlossen

Diese Studie läuft in
Städte
  • Frankfurt am Main
  • Großhansdorf
Studien-ID:

NCT01588184 2011-002009-31 MO25757

      Studienzentren finden

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden für Laien bearbeitet.

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden nicht geändert.

      Results Disclaimer

      Studienzusammenfassung

      This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the bevacizumab therapy. Participants will receive the same dose and regimen of bevacizumab as used in the previous parent trial and continue this treatment until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

      Hoffmann-La Roche Sponsor
      Phase 4 Phase
      NCT01588184, MO25757, 2011-002009-31 Studien-ID
      Bevacizumab Treatments
      Neoplasms Condition
      Official Title

      A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study

      Einschlusskriterien

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator
      • Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol
      • Able to comply with this extension study protocol (MO25757)
      Exclusion Criteria
      • Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study
      • Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation
      • A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial
      • Evidence of any other disease that would put the participant at high risk for treatment-related complications

      Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de

       

      Über klinische Studien

      Erfahren Sie mehr über klinische Studien und wie sie durchgeführt werden

      Erfahren Sie mehr